Solid Biosciences Inc. (SLDB) stock
SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.23−0.25 (-3.86%)
Close on Nov 17, 2026Market cap $668.01MP/E –Yield –
Solid Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Solid Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$186.84M. For fiscal 2025 it was -$156.29M. The highest annual figure on record is -$20.12M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$156.29M | – |
| FY2024 | Dec 31, 2024 | -$100.01M | – |
| FY2023 | Dec 31, 2023 | -$94.18M | – |
| FY2022 | Dec 31, 2022 | -$97.98M | – |
| FY2021 | Dec 31, 2021 | -$77.76M | – |
| FY2020 | Dec 31, 2020 | -$56.60M | – |
| FY2019 | Dec 31, 2019 | -$92.71M | – |
| FY2018 | Dec 31, 2018 | -$70.20M | – |
| FY2017 | Dec 31, 2017 | -$43.22M | – |
| FY2016 | Dec 31, 2016 | -$20.12M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$52.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$47.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$53.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$33.47M | – |
| Q2 FY2025 | Jun 30, 2025 | -$37.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.65M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.71M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.47M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.19M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$27.47M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$34.48M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.43M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.88M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.19M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.87M | -1697.1% |
| Q3 FY2021 | Sep 30, 2021 | -$18.42M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.10M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.37M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.31M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.56M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.07M | – |
| Q1 FY2020 | Mar 31, 2020 | -$29.27M | – |
| Q4 FY2019 | Dec 31, 2019 | -$21.25M | – |
| Q3 FY2019 | Sep 30, 2019 | -$19.24M | – |
| Q2 FY2019 | Jun 30, 2019 | -$26.30M | – |
| Q1 FY2019 | Mar 31, 2019 | -$25.93M | – |
| Q4 FY2018 | Dec 31, 2018 | -$21.40M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.29M | – |
| Q2 FY2018 | Jun 30, 2018 | -$16.33M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.17M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.98M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.44M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.61M | – |
| Q1 FY2017 | Mar 31, 2017 | -$10.20M | – |
See a number that looks wrong?